文档介绍：紫杉醇联合卡培他滨治疗晚期乳腺癌的临床观察
作者:刘桂平张良明孙萍耿冬梅
【摘要】目的评价紫杉醇联合卡培他滨治疗晚期乳腺癌的疗效和毒副作用。方法符合入组条件的晚期乳腺癌26例,化疗方案紫杉醇70~80 mg/(m2·d)静脉滴注,第1、8天;卡培他滨1 800 mg/(m2·d)分两次口服,第1~14天, 每3周为1个周期,连用2个周期,治疗结束2周后评价疗效,CR或PR者继用至4~6周期。结果 26例患者均可评价疗效,RR 50%(13例),其中CR 3例, PR 10例;主要毒副作用为骨髓抑制和胃肠道反应;% ,其中Ⅲ% ,无Ⅳ度发生;恶心、%,均可耐受;无治疗相关性死亡。结论紫杉醇联合卡培他滨是一个疗效肯定、毒副作用可耐受的方案。
【关键词】乳腺癌;紫杉醇;卡培他滨;药物治疗
【Abstract】 Objective To evaluate the therapeutic effects and toxicities of paclitaxel and capecitabine (Xeloda) combination regimen in the treatment of advanced breast 26 patients with advanced breast cancer were treated with TAX 7080 mg(m2·d) for day 1 and day 8 and capecitabine 1 800 mg/(m2·d) twice daily for day 1 to day 14 , repeated every 3 Twentysix patients were overall response rate was 50% , complete response was observed in 3 patients, partial response in 10 cases. The major toxicities including myelosuppression and nause
a/vomiting. Leukopenia was observed in most of patients(%)and grade Ⅲ leukopenia in 2 cases of the 26 patients(%) ,no grade Ⅳ. The rates of vomiting were % , and were tolerable. There was no death associated with treatment .Conclusion bined with capecitabine (Xeloda) regimen is effective and tolerable for patients with advanced breast cancer.
【Key words】 breast cancer,paclitaxel,capecitabine,chemotherapy
乳腺癌是危害广大妇女